MORE►
ZS Pharma
Frank Stonebanks, CEO of Renibus Therapeutics. [Photo: Renibus]
With New Funding and CEO, This Southlake Biotech is Looking to Solve Kidney Disease
by Kevin Cummings | Feb 16, 2022
Renibus Therapeutics, which focuses on treatments for acute and chronic kidney diseases, announced closing a $35 million Series A funding round. Its new CEO, Frank Stonebanks, says "Renibus has arrived at a critical inflection point in its commitment to transform the prevention and treatment of kidney diseases."
by Lauren Hawkins |
Jul 21, 2020
Nanoscope Therapeutics, a TechFW client, has closed an over-subscribed Series A funding round for its leading work on retinas, which could enable the blind to see.
In addition, Nanoscope has named Al Guillem as Chairman of the Board. Guillem (pictured below) was part of TechFW's greatest success story when ZS Pharma, a company he co-founded, was purchased by AstraZeneca for $2.7 billion.
In addition, Nanoscope has named Al Guillem as Chairman of the Board. Guillem (pictured below) was part of TechFW's greatest success story when ZS Pharma, a company he co-founded, was purchased by AstraZeneca for $2.7 billion.
MORE►
by Jeff Bounds |
Jan 22, 2020
Here are notable organizations that veterans of the eye care giant have started or hold executive positions in.
MORE►
![At the Fourth Annual iC3 Life Science Summit at UT Arlington on Oct. 10, 2017 recipient Lyda Hill will present the award. To register for the summit, visit www.bionorthtx.org. [Illustration: bestbrk/istockphoto]](https://s24806.pcdn.co/wp-content/uploads/2018/09/Bionorthconcept_970_bestbrk_istockphotovector-molecule-background-genetic-and-chemical-compounds-abstract-vector-id908258902-360x203.jpg)
by Alex Edwards |
Sep 27, 2018
2017 recipient Lyda Hill will present the award at the fourth annual iC3 Life Science Summit at UT Arlington on Oct. 10.
MORE►
